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Abstract
Background: Reconstruction of a segmental fracture with massive bone loss is still a challenge for orthopaedic
surgeons. The aim of our study was to develop a suitable biodegradable thermosensitive hydrogel system as a
carrier for bone morphogenetic protein (BMP)-2 delivery in the treatment of critical-sized femoral defects.
Methods: A block copolymer composed of monomethoxypoly(ethylene glycol) (mPEG), poly(lactic-co-glycolic acid)
(PLGA) and 2, 2’-Bis (2-oxazolin) (Box) was synthesized by ring opening polymerization. The synthesized block
copolymer was characterized by 1H-NMR spectroscopy and gel permeation chromatography (GPC). Different
biophysical and biochemical properties of the synthesized copolymer, including temperature-induced structure
changes, degradation rate, pH changes during hydrolytic degradation, cell toxicity, and the release profile of BMP-2,
were also evaluated and/or were compared with those of a well-characterized mPEG-PLGA copolymer. In animal
testing, rabbits (n = 36) that received critically sized (10 mm) femoral defects were divided into 6 groups. These
experimental groups included an untreated group, autograft, and groups treated with the synthesized copolymer
carrying different concentrations of BMP-2 (0, 5, 10, and 20 μg/ml). Bone repair was evaluated using X-ray
radiography, histological staining, micro-computed tomography (μCT), biomarker examination and biomechanical
testing in a 12-week treatment period.
Results: A new thermosensitive mPEG-PLGA/Box/mPEG-PLGA block copolymer, or named as BOX copolymer, was
successfully prepared. Compared to the reported mPEG-PLGA in vitro, the prepared BOX copolymer at the same
weight percent concentrations exhibited wider temperature ranges of gelation, slower degradation rates, higher the
pH values, as well as less cytotoxicity. Furthermore, the BMP-2 release from BOX hydrogel exhibited a near-linear
release profile in vitro. In animal experiments, treatment of critical-sized bony defects with 25 wt% BOX hydrogel
carrying BMP-2 effectively promoted fracture healing during the 12-week trial period and higher concentrations of
BMP-2 treatment correlated with better bone quality. Most importantly, clinical outcome and bone healing in the
BOX-hydrogel group with 20 μg/ml BMP-2 were nearly equivalent to those in the autograft group in a 12-week
treatment course.
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Conclusion: These data support that the use of BOX hydrogel (25 wt%) as a drug delivery system is a promising
method in the treatment of large bone defects.
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Background
Reconstruction of massive segmental bone defects
caused by trauma or tumor is still a significant clinical
challenge. Unsatisfactory clinical outcomes occur in
more than 30 % of patients with high-energy fracture
after surgical treatment [1]. Thus far, there are a variety
of interventions available to orthopedic surgeons to
manage extensive local bone loss, including autograft,
allograft and transplantation with synthetic bone substi-
tutes. Autograft, also known as autologous bone graft, is
considered to be a gold standard for bone replacement.
Although the use of autograft is considered as the gold
standard, some problems are encountered such as donor
site morbidity and limited donor bone supply [2, 3].
Allograft is an alternative way for bone regeneration in
which the graft bone is obtained from another individ-
ual. Several disadvantages have been reported for allo-
graft transplantation, including incomplete or delayed
graft incorporation, poor osteoinductivity, the potential
for eliciting a deleterious immune response, and the risk
of disease transmission [4, 5]. To circumvent these prob-
lems of autograft and allograft, various synthetic bone
substitutes such as hydroxyapatite, calcium phosphate
cements or biodegradable polymers have been developed
[6–8]. These synthetic bone substitutes provide the ben-
efits including availability, sterility and reduced morbid-
ity at the graft site.
Theoretically, an ideal bone graft material should in-
clude four characteristics: (i) osteointegration, the ability
to directly bond to the surface of host bone; (ii) osteo-
conduction, the ability to serve as a scaffold to guide the
growth of bone; (iii) osteoinduction, the ability to stimu-
late differentiation of osteoprogenitor cells into osteo-
blasts; (iv) osteogenesis, the formation of new bone by
osteoblasts present within the graft material [9]. Based
on criteria in the list, only autograft matches all of these
requirements, while allograft possesses osteointegrative,
osteoconductive and osteoinductive potentials. Cur-
rently, synthetic bone substitutes possess only osteointe-
grative and osteoconductive properties. Due to the lack
of osteoinductive and osteogenic abilities, one possible
approach to improving synthetic bone substitutes is to
incorporate bone morphogenetic protein 2 (BMP-2), the
most common cellular osteoinductive mediator that has
received FDA approval for the use in treating acute tibial
fractures [10]. In addition to exogenous BMP-2 treatment,
stem cell-based therapy using mesenchymal stem cells
(MSCs) has also received growing attention for bone re-
generation [11]. Although MSCs implanted in bone de-
fects are capable of conferring osteogenesis under certain
conditions, the potential risks of stem cell-based thera-
peutic applications are largely unknown [12].
Over the past decade, biodegradable polymers have
been extensively studied and used for a wide range of
biomedical applications [13]. Among these biodegrad-
able polymers, temperature-responsive hydrogels have
attracted great attention as scaffolds for tissue engineer-
ing or as carriers for bioactive molecules [14–17]. Com-
pared to other implantable or biodegradable systems,
temperature-responsive hydrogels may potentially give
equal or greater benefits to treat bone defects. First, the
sol-to-gel system provides an injectable design, which al-
lows surgical operation in a minimally invasive way. Sec-
ond, formulation or preparation of the thermogelling
system is free of harmful organic solvents. Third, an
irregular-shaped bone defect can easily be filled during
the sol-to-gel transition. Fourth, the use of the thermo-
gelling system has a high encapsulation rate for drug or
bioactive molecules. Previously, we have developed a
biodegradable thermosensitive hydrogel copolymer, the
amphiphilic monomethoxypoly (ethylene glycol)-co-
poly(lactic-co-glycolic acid) (mPEG-PLGA), which has
been used as a drug carrier in treating osteomyelitis [18].
Although the use of mPEG-PLGA copolymer as a drug
carrier appears to be an effective approach for the treat-
ment of osteomyelitis, several biochemical properties of
mPEG-PLGA copolymer potentially limit its applications
in the reconstruction of large bone defects. For exam-
ples, the degradation products such as lactic acid and
glycolic acid released from mPEG-PLGA hydrogel may
lead to a transient pH reduction, which raises concerns
regarding local acidosis or inflammation [19, 20]. An-
other potential drawback is that the degradation rate of
mPEG-PLGA hydrogel is fast (50 % within 2 weeks),
which is unfavorable if we need to extend drug release
for a longer time period.
In the report, we aimed to develop a suitable thermo-
sensitive biodegradable hydrogel for BMP-2 delivery to
treat critical-sized bone defect. A modified mPEG-PLGA
copolymer that contains an additional linkage of 2, 2’-
Bis (2-oxazolin) (Box) was prepared here and was desig-
nated as mPEG-PLGA/Box/mPEG-PLGA copolymer or
“BOX” hydrogel. Compared to mPEG-PLGA hydrogel in
vitro, the BOX hydrogel exhibited wider gelling
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temperature ranges, slower degradation rates, and higher
the pH before and after degradation. In the in vivo
examination, BOX hydrogels loaded with different con-
centrations of BMP-2 were used to treat a critical-sized
(10 mm) femoral defect in NZW rabbits. The outcomes
of different treated groups were evaluated using X-ray
radiography, histological staining, micro-computed tom-
ography (μCT), biomarker examination and biomechan-
ical testing. Our results demonstrated that implantation
of the BMP-2-loaded BOX hydrogel is an efficient




D,L-lactide and glycolide were purchased from Purac
(Netherlands). Poly (ethyleneglycol) monomethyl ether
(mPEG) (Mn, 550 g/mol) as an initiator was purchased
from Polyscience (Warrington, PA, US). Stannous 2-
ethylhexanoate (Stannous Octoate) was obtained from
Sigma Aldrich (Poole, UK). Succinic anhydride was pur-
chased from Fluka (St. Louis, MO, US). Recombinant
human bone morphogenetic protein 2 (BMP-2) was pur-
chased from Peprotech (Rocky Hill, NJ, US). All other
chemicals were used as HPLC grade or extra pure grade.
Synthesis of BOX copolymer
BOX copolymer, also referred to as mPEG-PLGA/Box/
mPEG-PLGA, was synthesized by the ring-opening
polymerization of monomers. A synthetic procedure is
shown in Scheme 1. Briefly, 10.04 g of mPEG, 20 g of
lactide, and 5.64 g of glycolide were initially added to the
reactor and the temperature was elevated slowly for dis-
solving the added substances. When the temperature
reached and was sustained at 160 °C, 14.0 μl of catalyst
(stannous 2-ethyl-hexanoate) was added. After stirring
for 8 h, the mPEG-PLGA polymer subunit was obtained.
Next, 1.84 g of succinic anhydride (with a molecular
weight of 100.07 g/mol) was added into the reactor.
After stirring for 4 h, 1.28 g of 2, 2’-Bis (2-oxazolin)
(Box) (with a molecular weight of 140.14 g/mol) was
added into the reactor. Once the mixture was com-
pletely melted, stannous 2-ethylhexanoate as a catalyst
was added into the reactor. After polymerizing for
4 h, the product was precipitated with diethyl ether/
n-hexane (v/v = 1/9). The resulting copolymers were
washed three times and vacuum-dried for 24 h at
40 °C.
Gel permeation chromatography (GPC)
The molecular weights of the synthetic mPEG-PLGA
and BOX copolymers were determined using an Agilent
GPC Addon apparatus and a RI-150 refractive index sig-
nal detector coupled to Plgel® columns. Tetrahydrofuran
served as a chromatographic solvent at 1 ml/min flow
rate in the assay and polystyrene standards were used
for calibration.
1H Nuclear Magnetic Resonance (1H NMR)
1H NMR spectroscopic analysis was performed in CDCl3
using an NMR instrument (BRUKER DRX400) at
400 MHz at room temperature. The number-average
molecular weight (Mn) and the LA/GA ratio were deter-
mined by integration of the signals pertaining to each
monomer.
Determination of sol-gel-sol phase transition by the test
tube inverting method
Solutions of hydrogel copolymers in deionized water
from 5 to 30 wt% were prepared and stored in vials at
4 °C. After 24 h, the vials containing polymer solutions
were immersed in a water bath at 5 °C, and the phase
transition of polymer solutions was investigated by rais-
ing the bath temperature from 5 to 60 °C in increments
of 1.0 °C. The phase transition temperature was taken as
the first temperature at which the solution did not flow
when tilted.
Determination of sol-gel-sol phase transition by rheomter
The rheological properties of hydrogel copolymers (in
sterile distilled water) were measured using AR-2000EX
Rheometer with plate/plate measuring systems and
TRIOS application software. The plates were equili-
brated to the starting temperature (5 °C) and
temperature sweep tests were carried out from 5 to 60 °
C. The temperature ramp rate was 0.1 °C/min. Fre-
quency of 1 Hz and the controlled shear strain (1 %)
with a deflection angle of 0.5 rad were employed.
Degradation and pH change of hydrogel copolymers
One milliliter of mPEG-PLGA or BOX hydrogel copoly-
mers (20 wt%) were incubated in 15 ml of phosphate
buffered saline (PBS), normal saline (0.9 % NaCl), or dis-
tilled water in air-tight vials and the mixed samples were
stirred with a speed of 50 rpm at 37 °C. After the indi-
cated incubation periods, the pH of upper layer solution
in each sample was measured. Triplicate hydrogel sam-
ples were determined at each time point. To determine
the degradation of hydrogel copolymers, solid residues
in vials were briefly rinsed with deionized water, lyophi-
lized and weighed.
Cytotoxicity assay
L929 is a murine fibroblast cell line and hFOB1.19 a hu-
man fetal osteoblastic cell line. L929 cells were cultured
in Eagle’s minimum essential medium supplemented
with 10 % horse serum, while hFOB1.19 cells were cul-
tured in a 1:1 mixture of phenol red-free DMEM and
Peng et al. BMC Musculoskeletal Disorders  (2016) 17:286 Page 3 of 14
Ham’s F-12 medium supplemented with 0.3 mg/ml G418
and 10 % fetal bovine serum. The leachates of mPEG-
PLGA and BOX hydrogel copolymers were prepared by
using 1 ml of hydrogel copolymers (5–30 wt%) that were
incubated with 15 ml of PBS at 37 °C for 24 h. L929 or
hFOB1.19 cells (1 × 104) were plated on 96-well plates
and cultured in the mixture of the culture medium and
copolymer supernatants at a ratio of 1:1 (60 μl: 60 μl).
Cell proliferation was evaluated with tetrazolium-based
colorimetric assay (XTT assay; Roche). Triplicate sam-
ples were examined for each cell line and each experi-
ment was repeated at least three times.
Intracutaneous irritation test
All animal experimental protocols in the study were
approved by the Institutional Animal Care and Use
Committee of the Chang Gung Memorial Hospital. The
3-month-old New Zealand White (NZW) rabbits weigh-
ing 2.5–3 kg were purchased from the Taiwan Livestock
Research Institute, Council of Agriculture, Executive
Yuan. The animals were then maintained in the Labora-
tory Animal Center (ISO9001: 2008) of Chang Gung Me-
morial hospital at Chiayi. Five intradermal injections of
each 0.2 ml BOX hydrogel with 20, 25 and 30 wt% were
given to the fur-clipped skin of NZW rabbits. The skin ir-
ritation was evaluated at 24, 48 and 72 h after injection.
BMP-2 release in vitro
The BOX-hydrogel copolymer was sterilized using 15 W
UV light for 24 h and recombinant BMP-2 (100 μg) was
added into 4 ml of 15, 20, 25 and 30 wt% copolymer
aqueous solution. One milliliter of the BMP-2/polymer
Scheme 1 Schematic diagram of the synthesis of BOX hydrogel copolymer
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formulation was loaded into the button of 10 ml release
cell and kept at 37 °C for 5 min to form the solid gel,
and then 9 ml PBS solution was added to the release
cell. The release cell was maintained at 37 °C in a
thermostat bath at a shaking rate of 50 rpm. Levels of
BMP-2 were determined by reversed-phase HPLC. One
milliliter of sample solution was first filtered through
0.2 μm filter and then applied to a HPLC system
(JASCO LC-2000) on a reversed-phase column (Hyper-
sil® PEP HS C18, 4.6 × 250 mm, Thermo, US). The con-
centration of BMP-2 was calculated by external
standardization method.
Creation of critically sized (10 mm) femoral defects
The 3-month-old NZW rabbits, weighing 2.5–3 kg, were
used for this study. 36 total rabbits were divided into 6
groups and each group contains 6 rabbits. These 6
groups included an untreated group, autograft, and
groups treated with BOX hydrogels containing different
concentrations of BMP-2 (0, 5, 10, and 20 μg/ml). All
rabbits fasted for 1 day before surgery. Anesthesia was
performed with ketamine (25 mg/kg) and xylazine
(10 mg/kg) by intravenous injection. The incision was
made on the lateral surface and extended down to the
middle femur. A MicroHall oscillating saw (Linvatek,
Largo, FL) was used to create a 10 mm length bony de-
fect in the middle shaft of the femur. The osteotomized
femur was stabilized with a stainless plate (DC-Plate,
Synthes, Davos, Switzerland), screws and multiple loop-
ing wires. Implant materials including autologous bone
and 1 ml of BOX hydrogels with or without BMP-2 were
inserted into the segmental defects at the right femora
of NZW rabbits. As noted, autologous bones (10 mm)
were cut into small pieces (2–3 mm) using a bone ron-
geur and then re-implanted into the defect site.
Radiographic analysis and μCT
The X-ray images were analyzed using the PMOD soft-
ware (PMOD Technologies, Zu rich, Switzerland) to de-
fine areas of the occupying callus and the original defect.
Based on the X-ray radiography, the bone was consid-
ered healed if i) contiguous calluses spanning both prox-
imal and distal ends of bony defects were observed, and
ii) the area of the newly formed bone exceeded 25 % of
the defect area. After 12 weeks, rabbits were sacrificed
and all femora were scanned with an animal μCT im-
aging system (Skyscan 1076, Bruker, Belgium). Bone
density in the osteotomized site with 10 × 10 mm area
was measured and calculated by μCT software provided
in the system (CT Analyser, Bruker, Belgium).
Histological staining
Femoral bone samples were fixed in neutral-buffered
formalin and decalcified with 0.6 N HCl. A 3-cm
segment in the mid-shaft of the diaphysis (encompassing
the graft) was cut, embedded in paraffin and sectioned
longitudinally (8 mm thick). The sections from the mid-
defect region were stained with hematoxylin and eosin
(H&E).
Biomechanical testing
The strength of femur specimens from all rabbit samples
(N = 36) in 6 treatment groups was evaluated by destruc-
tive biomechanical testing. The proximal and distal ends
of specimens were embedded in polymethylmethacrylate
blocks and rigidly mounted on a universal testing ma-
chine (MTS; Minneapolis, MN). The distal end of the
specimen was rotated laterally at a constant deformation
rate of 1.0° per minute until bone failure occurred. The
maximum torque at failure (N-mm), the angle at failure
(deg) and torsional stiffness (N-mm/deg) were computed
according to the applied load and angular displacement
curves.
Western blot analysis
Bone specimens were homogenized and lysed in a pro-
tein extraction reagent (Tissue protein extraction re-
agent, Pierce, Rockford, US) containing protease
inhibitors (Protease Inhibitor cocktail, Sigma-Aldrich,
US). Western blot analysis was carried out according to
our previous publication [18]. Antibodies specific to col-
lagen I (COL1A1; ab34710, Abcam, UK), osteocalcin
(OC; ab13418, Abcam, UK), and alkaline phosphatase
(ALP; sc-28904, Santa Cruz, US) were used at 1:1000.
The HRP-conjugated anti-mouse and anti-rabbit second-
ary antibodies, (Chemicon, US) were used at 1:5000.
After extensive washing steps, the membranes were in-
cubated with ECL substrates (Millipore, US).
Statistical analysis
A Student’s t-test was used to compare the biophysical
and biochemical properties between mPEG-PLGA and
BOX copolymers. The differences of clinical outcomes
or biomarker expression between the untreated group
and treated groups were statistically analyzed using
Kruskal Wallis (KW) test. P < 0.05 was considered to be
statistically significant.
Results
Preparation of BOX copolymer
BOX copolymer, or mPEG-PLGA/Box/mPEG-PLGA, is
synthesized as shown in Scheme 1 and the 1H NMR
spectrum of BOX copolymer is given in Fig. 1. The com-
plicated splits in these peaks are due to random
copolymerization of glycolide (GA) and lactide (LA).
The characteristic signals appearing at 7.8, 5.2, 4.8, 4.2,
3.6, 3.3, 2.6 and 1.5 ppm represent NH of 2, 2’-Bis (2-
oxazolin) (Box), CH of LA, CH2 of GA, CH2O of mPEG,
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CH2 of mPEG, OCH3 of mPEG, CH2 of SA, and CH3 of
LA, respectively. The LA-to-GA ratio determined by 1H
NMR spectroscopy matched very well with the initial ra-
tio (78:22) of the added monomers. As expected, the cal-
culated molecular weight averages (Mw and Mn) of
BOX copolymer were more than twice (2.37 to 2.40) as
high as those of the parental mPEG-PLGA copolymer
(Table 1). Furthermore, a narrow molecular weight dis-
tribution (MWD; Mw/Mn) around 1.38 to 1.40 was ob-
tained in both copolymers (Table 1).
Thermosensitive sol-gel-sol transition of mPEG-PLGA and
BOX copolymers
To compare the sol-to-gel-to-sol behaviors between
BOX and mPEG-PLGA copolymers, the phase transition
was determined by both the test tube inverting method
and rheometer. Aqueous solutions of copolymers at con-
centrations from 5 to 30 wt% were first prepared in de-
ionized water (4 °C). All samples of both copolymers
were shown as a translucent emulsion solution at 4 °C.
The phase transition diagrams of both copolymers deter-
mined by the test tube inverting method are shown in
Fig. 2a. Both hydrogel copolymers exhibited three physical
states: solution, gel, and precipitate in responding to dif-
ferent temperatures. When the copolymer concentrations
were gradually increased from 5 to 30 wt%, the solution-
to-gel (sol-gel) transition temperatures were gradually
decreased and the gel-to-precipitate (gel-sol) transition
temperatures were raised. The critical gelation concentra-
tions (CGCs) of the mPEG-PLGA-hydrogel and BOX-
hydrogel copolymers were estimated to be 4.0 wt% (Fig. 2a,
tips of the U curves). Based on the testing, BOX hydrogel
showed similar the sol-gel transition temperatures to
mPEG-PLGA hydrogel, but had higher the gel-sol transi-
tion temperatures than mPEG-PLGA hydrogel.
When the sol-gel-sol transition of both mPEG-PLGA
and BOX hydrogels was determined by rheometer
(Fig. 2b), we found that the gel-sol transition tempera-
tures measured by the test tube inverting method or by
rheometer could vary by 40 %. Noteworthily, the gel-sol
transition temperatures of BOX copolymer measured by
rheomter were much higher (up to 10 °C) than those of
mPEG-PLGA copolymer.
In addition to the sol-gel-sol transition described
above, we also compared the gelling time of mPEG-
PLGA and BOX copolymers with different concentra-
tions (15, 20, 25 and 30 wt%) at 37 °C (Table 2). In gen-
eral, the gelation times of BOX solutions were relatively
shorter than those of mPEG-PLGA solutions (32–145 s
versus 43–163 s).
In vitro degradation of mPEG-PLGA and BOX hydrogels
Both mPEG-PLGA and BOX hydrogels copolymers with



















Fig. 1 1H NMR spectrum of BOX copolymer plotted as signal intensity (vertical axis) vs. chemical shift (in ppm on the horizontal axis). * H2O;
# CDCl3
Table 1 The molecular weight averages and molecular weight





mPEG-PLGA hydrogel 2257 1635 1.38
BOX hydrogel 5415 3867 1.40
aMw: The weight average molecular weight
bMn: The number average molecular weight
cMWD: Molecular weight distribution
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37 °C, and the weight loss of both copolymers was mea-
sured within 4 weeks (Fig. 3). We found that mPEG-
PLGA and BOX hydrogels in PBS or in normal saline
had slower degradation rates than those in water (Fig. 3),
suggesting that physiological or chemical buffering sys-
tems could slow down the degradation of these two co-
polymers. Under the same conditions, BOX hydrogels
exhibited slower degradation than mPEG-PLGA hydro-
gels. For example, mPEG-PLGA and BOX hydrogels in
PBS or in normal saline were degraded by 70 and 30 %,
respectively, at 4-week incubation.
pH changes in mPEG-PLGA and BOX hydrogels during
hydrolytic degradation
Due to the presence of the basic 2,2’-Bis(2-oxazoline)
group in the BOX copolymer, the prepared BOX hydro-
gel displayed higher the pH than the corresponding
mPEG-PLGA hydrogel before hydrolytic degradation
(pH 5.4 versus pH 4.2). After incubation with PBS, nor-
mal saline or water, both mPEG-PLGA and BOX copoly-
mers underwent hydrolytic degradation and pH values
were gradually decreased over time (Fig. 4). Although
pH values were reduced for both copolymers after
hydrolytic degradation, BOX hydrogel consistently
showed pH values higher than those of mPEG-PLGA
hydrogel during the 4-week trial period.
Cytotoxicity of mPEG-PLGA and BOX hydrogels
To test cytotoxicity of mPEG-PLGA and BOX copoly-
mers in vitro, L929 mouse fibroblasts and hFOB1.19 hu-
man osteoblastic cells were included in the study. Both
L929 and hFOB1.19 cells were cultured in a 1:1 mixture
of the culture medium and the leachates of copolymers
(5 to 30 wt%). Proliferation of the cultured cells was
evaluated on day 1 and day 3 by XTT assay. There were
no obvious differences between mPEG-PLGA- and
BOX-treated groups in either L929 or hFOB1.19 cells on
day 1 (Fig. 5). However, at day 3 of the culture, we found
that the leachates of BOX copolymer at high-
concentration formulations (>15 wt%) were less toxic
than those of mPEG-PLGA copolymer on both L929
and hFOB1.19 cells (Fig. 5).
To further determine the toxicity of BOX hydrogel co-
polymer in vivo, the intracutaneous irritation test was
carried out in rabbits. BOX hydrogels with 20, 25 and
30 wt% formulations were intracutaneously injected
(0.2 ml per site) into rabbits and skin irritation was eval-
uated at day 1, 2 and 3 after injection. We found that in-
jection of the BOX hydrogel in rabbits did not show any
signs of skin irritation over 3 days (Fig. 6).
BMP-2 release from BOX hydrogel in vitro
The release profiles of BMP-2 (25 μg/ml) from BOX
hydrogels at different copolymer concentrations (15,
20, 25 and 30 wt%) in vitro are shown in Fig. 7.
Lower concentrations of copolymer appeared to re-
lease more BMP-2 within a 4-week incubation period.
At 4 weeks, the measured amounts of BMP-2 released
from 15, 20, 25 and 30 wt% Box hydrogels were 48,
43, 22 and 6 %, respectively (Fig. 7a). In parallel, we
observed that free BMP-2 was unstable in the solu-
tion and up to 50 % of BMP-2 underwent proteolytic
degradation at 37 °C after 4-week incubation (Fig. 7a,
BMP-2 alone). After normalization of the measured
amounts of BMP-2 released from hydrogels to the
amounts of free BMP-2 in the solution at the
Concentration (wt %)
















































Fig. 2 Sol-to-gel-to-sol phase diagrams of mPEG-PLGA and BOX
hydrogel copolymers in deionized water. The phase transition tem-
peratures were measured by the tube inverting method (a) and by
rheometer (b)
Table 2 Gelling time for hydrogel (seconds)
mPEG-PLGA hydrogel (mean ± SD) BOX hydrogel (mean ± SD)
15 wt% 163 ± 7 145 ± 6
20 wt% 98 ± 5 95 ± 5
25 wt% 79 ± 5 58 ± 4
30 wt% 43 ± 3 32 ± 2
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indicated time points, a nearly linear BMP-2 release
from BOX hydrogels was obtained (Fig. 7b). The nor-
malized BMP-2 release rate from BOX hydrogels at
4 weeks was about twice as high as the unnormalized
BMP-2 release rate shown in Fig. 7a.
Treatment of critical-sized bone defects with the BMP2-
loaded BOX hydrogel
Based on the BMP-2 release profiles shown in Fig. 7, we
chose 25 wt% BOX hydrogel for BMP-2 delivery to treat
fracture nonunions in rabbits. One milliliter of the BOX
hydrogel alone or the BOX hydrogel loaded with 5, 10
or 20 μg of BMP-2 was injected into the femoral osteot-
omy gap (10 mm) in the rabbit model. In addition to
BOX-hydrogel groups, two control groups including
autograft and the untreated group were also included in
the study. At 4, 8 and 12 weeks after treatment, bone
healing was visualized by X-ray radiography. The repre-
sentative radiographs are shown in Fig. 8. Radiographic
healing did not occur in both the untreated (0/6) and
BMP-2-free hydrogel groups (0/6) at 8 and 12 weeks
(Table 3). Treatment with the BOX hydrogel contain-
ing the low dose of BMP-2 (5 μg/ml) healed some
bone defect with a radiographic healing rate 16 %
(1/6) and 33 % (2/6) at 8 and 12 weeks, respectively.
Bone regeneration was further enhanced in the
BMP-2 (10 μg/ml)-loaded hydrogel group with a
healing rate 50 % (3/6) at 8 weeks and 67 % (4/6) at
12 weeks. Both the autograft and high-dose BMP-2
(20 μg/ml) treated groups demonstrated 100 % heal-
ing rate (6/6, and 6/6) at 8 and 12 weeks (Table 3).
To further verify bone healing of the nonunion
after BMP-2 treatment, sample sections were sub-
jected to hematoxylin and eosin (H&E) staining
(Fig. 9). Three BMP-2-loaded hydrogel groups dis-
played better bone regeneration than the untreated
and BMP-2-free hydrogel groups. Especially, the
hydrogel group with the high-dose BMP-2 (20 μg/ml)
offered bone healing more effectively than the other
BMP-loaded hydrogel groups, and the resulting bone
growth was comparable to that in the autograft group
(Fig. 9).
Evaluation of bone repair by the examination of bone
remodeling markers
The expression of bone-specific turnover markers,
including alpha-1 type I collagen (COL1A1), alka-
line phosphatase (ALP) and osteocalcin (OC), was
evaluated in the nonunion animal model after
treatments. In parallel, bone samples obtained from
healthy femora were also included as positive con-
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Fig. 3 Degradation of mPEG-PLGA and BOX hydrogels in vitro. Both mPEG-PLGA and BOX hydrogels at a concentration of 20 wt% were
immersed in 15 ml of PBS (a), normal saline (b) or distilled water (c). The mass loss of both copolymers was measured at 37 °C in a 4-week
























































Fig. 4 Changes in the pH of mPEG-PLGA and BOX hydrogels before and after degradation. The pH of mPEG-PLGA and BOX hydrogel copolymers
was measured after immersion in PBS (a), saline (b) or distilled water (c) for 0, 1, 2 and 4 weeks. *P < 0.05, the statistical comparisons for BOX
hydrogel versus mPEG-PLGA hydrogel
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b
Fig. 5 In vitro cytotoxicity of mPEG-PLGA and BOX hydrogel copolymers. The leachates of mPEG-PLGA or BOX hydrogels (5–30 wt%) were prepared
as described in Materials and Methods. L929 cells (a) and hFOB1.19 cells (b) were cultured for 1 or 3 days in the 1:1 mixed medium of culture media



















Fig. 6 Intracutaneous irritation test. (a) Diagram of arrangement of injection sites for tested samples (including normal saline and the BOX hydrogel at
20, 25 and 30 wt%) in rabbits. (b) Five intradermal injections of each 0.2 ml normal saline or the BOX hydrogel with different formulations (20, 25 and
30 wt%) were given to the fur-clipped skin of rabbits (N = 3). The skin irritation was evaluated at day 1, 2 and 3 after injection
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untreated and BMP-2-free hydrogel groups, the autograft
and BMP-2-loaded hydrogel groups showed higher ex-
pression levels of COL1A1 (Fig. 10a and b; P < 0.05). As
expected, the protein abundance of COL1A1 in these
treated groups positively correlated with the bone healing
detected by X-ray radiography and by H&E staining
(Fig. 10a). We also found that, like healthy bone
controls, bone samples from the autograft and
BMP-2-loaded hydrogel groups consistently had
lower expression levels of ALP and OC, two early
markers of osteoblastic differentiation, than the un-
treated and BMP-2-free hydrogel groups (Fig. 10a,
c and d; P < 0.05).
Bone healing evaluated by gross appearance and μCT
analysis
At 12 weeks after treatment, rabbits were sacrificed and
the femora were prepared for macroscopic observation
and μCT bone analysis. The untreated and BMP-2-free
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a b
Fig. 7 The release profiles of BMP-2 from BOX hydrogels with different copolymer concentrations. a The amounts of BMP-2 released from 15, 20,
25 and 30 wt% BOX hydrogels at indicated incubation time points were determined by reversed-phase HPLC. Soluble BMP-2 in the solution (PBS)
for different time periods was also included in the study. b The release profiles of BMP-2 were plotted after the amounts of BMP-2 released from
BOX hydrogels were normalized with the amounts of free BMP-2 in the solution at the corresponding time points





BOX hydrogel + BMP-2 (µg/ml)
Fig. 8 Representative radiographs of untreated and treated femora in rabbits with a critical-sized bone defect. Rabbits that received a 10 mm-long
bone defect at the middle of the femur were untreated or treated with autograft bone or BOX hydrogels loaded with different concentrations of BMP-
2. The untreated and treated femora at 4, 8 and 12 weeks after operation were examined by X-ray radiography. Red arrows indicate bony defect sites
at the femur, and yellow arrows show bridging callus
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defects according to gross appearance (Fig. 11), and
the callus did not bridge across the defective areas in
these two groups as confirmed by μCT images
(Fig. 11). Treatment with BOX hydrogels carrying low
or medium BMP-2 (5 μg/ml or 10 μg/ml) promoted
the formation of contiguous callus spanning the ends
of the bony defect, but not yet fully ossified. Import-
antly, the complete cortical bone healing was ob-
served in the hydrogel group loaded with 20 μg/ml
BMP-2 and in the autograft group. Table 4 shows the
bone density of different treated groups measured by
μCT.
Table 3 Radiographic assessment of bone defect healing in
rabbits
Groups Number of animals with
radiographic healing
8 weeks 12 weeks
Untreated 0/6 0/6
Autograft 6/6 6/6
BOX hydrogel 0/6 0/6
BOX hydrogel + 5 μg/ml BMP-2 1/6 2/6
BOX hydrogel + 10 μg/ml BMP-2 3/6 4/6















Fig. 9 Histological analysis (H&E stain, 200x) of bone regeneration in
femoral defect rabbits after treatment. The tissue sections from the
mid-defect femur regions of rabbits were prepared and stained with
hematoxylin and eosin. Homogenous red staining: bone collagen;
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Fig. 10 Expression of bone regeneration markers in femoral defects
after treatment. a After 12-week treatments, the indicated samples
were examined for the expression of COL1A1, ALP and OC by Western
blot analysis. After normalization with the β-actin content, the relative
expression levels of COL1A1, ALP and OC were shown in (b, c and d).
Healthy: healthy femora, *P < 0.05 compared to the untreated group
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Biomechanical tests of bone healing
Tables 5 and 6 show the torsional stiffness and max-
imum torque of all femora obtained from different
treated groups. The untreated or BMP-2-free hydrogel
group displayed extremely low torsional stiffness and
maximum torque relative to those of the autograft
and BMP-2-loaded hydrogel groups. Compared to
autograft, the BOX-hydrogel groups loaded with 5, 10
and 20 μg/ml of BMP-2 had a similar torsional stiff-
ness (174.5, 182.2 and 223.3 N-mm/deg versus
200.8 N-mm/deg) and maximum torque (733, 770.8
and 909.3 N-mm versus 713 N-mm). Our results re-
vealed that the thermosensitive BOX hydrogel carry-
ing BMP-2 represents an effective method for
repairing large bone defects.
Discussion
Thus far, repair of large bone defects still remains a
challenge for orthopaedic surgeons. Studies have re-
ported that natural or synthetic materials could serve
as bone graft substitutes or as drug delivery vehicles
in bone tissue regeneration [21–25]. Although many
advantages of these materials have been reported, an
easy-to-prepare biomaterial with desired properties
still remains to be developed. In the study, we de-
velop a new thermosensitive hydrogel, named as
“BOX”, for BMP-2 delivery to treat fracture non-
unions in rabbits. To our knowledge, this is the first
report to apply a thermosensitive hydrogel as a BMP-
2 carrier to treat large bone defects. In our critical-
sized bone defect model, we show that the BOX
hydrogel carrying BMP-2 is an effective strategy to
treat the nonunion and the resultant bone healing
can be comparable to that treated with autologous
bone grafting.
mPEG-PLGA hydrogel has previously been developed
as a carrier for antibiotics to treat osteomyelitis [18]. Dif-
ferent biophysical and biochemical properties between
mPEG-PLGA and BOX hydrogels in vitro have been
compared in the study (Figs. 2, 3, 4 and 5). There are at
least five reasons that prompted us to choose BOX
hydrogel, but not mPEG-PLGA hydrogel, as a BMP-2
carrier for the treatment of fracture nonunions. First,
BOX hydrogel has a wider temperature range for gel-
ation than the corresponding mPEG-PLGA hydrogel
(Fig. 2), indicating that BOX hydrogel would be more
stable than mPEG-PLGA hydrogel in the body. Second,
BOX hydrogel has a slower degradation rate than
mPEG-PLGA hydrogel under physiological and chemical
buffering systems (Fig. 3). The degradation rate of
BOX hydrogel (30 % in 4 weeks) is suitable for the
treatment of nonunion in a 12-week course. Third,
BOX hydrogel exhibits higher the pH than mPEG-
PLGA hydrogel during hydrolytic degradation (Fig. 4).
Despite the fact that acidic degradation products (lac-
tic acid and glycolic acid) released from mPEG-PLGA
or BOX hydrogel could be easily metabolized in the
body, transient pH reduction at local implant sites is
still the concern for the use of PLGA-based copoly-
mers in vivo [19, 20]. Due to the presence of a basic
2,2’-Bis(2-oxazoline) group, BOX hydrogel consistently
displays higher the pH values than mPEG-PLGA.
Although BOX hydrogel is still slightly acidic (pH5.4),
several studies have previously reported that mild
acidic conditions were actually favorable for the
osteoinductive activity of BMP-2 in vivo [21, 26].
Fourth, BOX hydrogel is less toxic to cultured cells
than mPEG-PLGA hydrogel (Fig. 5). Fifth, a near-
linear release profile of BMP-2 from the BOX hy-












Fig. 11 Bone healing evaluated by gross appearance and
μCT analysis
Table 4 Bone mineral density (in grams per square centimeter,
g/cm2)
Groups Mean ± SD p
Untreated 0.37 ± 0.03
Allograft 0.80 ± 0.09 0.000a
BOX hydrogel 0.41 ± 0.05 0.140
BOX hydrogel + 5 μg/ml BMP-2 0.61 ± 0.06 0.001a
BOX hydrogel + 10 μg/ml BMP-2 0.73 ± 0.05 0.000a
BOX hydrogel + 20 μg/ml BMP-2 0.90 ± 0.08 0.000a
acompared to the untreated group
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period (Fig. 7). Herein, we chose 25 wt% BOX hydro-
gel in our animal experiments.
In addition to BMP-2-loaded BOX-hydrogel groups,
three experimental control groups were also covered in
the study, including an untreated group, autograft, and a
BMP2-free hydrogel group. In a 12-week treatment
course, bone healing was evaluated using X-ray radiog-
raphy, histological staining, micro-computed tomography
(μCT), biomarker examination and biomechanical testing
(Figs. 8, 9, 10 and 11 and Tables 3, 4, 5 and 6). According
to our results, treatment with BOX hydrogel carrying
higher doses of BMP-2 closely correlated with better
fracture healing in rabbits. The dose-dependent thera-
peutic effects strongly suggested that the selected
BOX formulation (25 wt%) is suitable to act as a drug
carrier for BMP-2 delivery in the animal model. Par-
ticularly, treatment of critical-sized bone defects with
the BOX hydrogel carrying 20 μg of BMP-2 exhibits
excellent outcomes that are similar to those seen in
rabbits treated with autologous bone graft.
When the biomarkers of bone formation were exam-
ined, we found that differential expressions of COL1A1,
ALP and OC were detected in different treatment
groups (Fig. 10). As expected, the expression levels of
COL1A1 were correlated with bone healing in these
treated groups (Fig. 10a and b). However, the levels of
ALP and OC were inversely associated with bone healing
in our study (Fig. 10a, c and d). COL1A1, ALP and OC
are mainly expressed from osteoblasts. During the heal-
ing of bone fracture, osteoprogenitor cells from sur-
rounding tissues initially differentiate into osteoblasts,
which play a vital role for bone formation and repair.
Upon full healing of the bone defect, osteoblasts in bone
matrix will transform into osteocytes, the most common
cells in mature bone. Therefore, the optimal expression
of OC and ALP is believed to occur early during osteo-
blastic differentiation, but down-regulation of these two
markers will be seen after the bone healing is complete. It
is consistent with our findings that healthy bones had
higher COL1A1 levels but lower ALP and OC levels than
broken bones that left untreated (Fig. 10). According to
the expression profile of these biomarkers in these treated
groups (Fig. 10), we conclude that low amounts of
COL1A1 in combination with high amounts of ALP and
OC in the untreated group and in the BMP2-free hydrogel
group reflect a state of incomplete bone healing.
Conclusion
The temperature-responsive BOX copolymer, or mPEG-
PLGA/Box/mPEG-PLGA, has been successfully prepared
and characterized. Based on the in vitro and in vivo testing,
we suggest that the use of the thermosentive BOX hydrogel
with BMP-2 may hold promise as an alternative therapeutic
strategy for the treatment of large bone defects.





BOX hydrogel + BMP-2 (μg/ml) (n = 6)
0 5 10 20
3 225 16 132 262 302
6 182 0 210 205 250
18 150 5 238 240 223
0 272 6 210 154 163
5 120 5 112 124 242
8 280 2 145 108 160
Mean ± SD 6.7 ± 5.6 200.8 ± 59.6a 5.7 ± 5.1 174.5 ± 46.8a 182.2 ± 57.6a 223.3 ± 49.8a
aP < 0.05 compared to the untreated group. n = 6 in each group





BOX hydrogel + BMP-2 (μg/ml) (n = 6)
0 5 10 20
30 588 38 565 798 1215
26 750 15 885 695 995
36 665 55 750 1006 685
10 840 26 852 658 598
26 780 31 648 612 1305
18 655 26 698 856 658
Mean ± SD 24.3 ± 8.4 713.0 ± 84.9a 31.8 ± 12.4 733.0 ± 111.2a 770.8 ± 133.5a 909.3 ± 279.2a
aP < 0.05 compared to the untreated group. n = 6 in each group
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